Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Spero Therapeutics (NASDAQ:SPRO) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research note issued on Sunday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.

Spero Therapeutics Stock Performance

NASDAQ SPRO opened at $2.33 on Friday. Spero Therapeutics has a one year low of $0.51 and a one year high of $3.22. The stock has a 50 day moving average price of $2.35 and a 200-day moving average price of $2.31. The company has a market capitalization of $131.27 million, a P/E ratio of 19.42 and a beta of 1.45.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Thursday, March 26th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.73. The firm had revenue of $41.30 million for the quarter, compared to analyst estimates of $26.00 million. Spero Therapeutics had a net margin of 12.83% and a return on equity of 27.61%. As a group, equities analysts predict that Spero Therapeutics will post -1.2 EPS for the current fiscal year.

Insider Activity at Spero Therapeutics

In other news, insider Esther Rajavelu sold 87,917 shares of the company’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.36, for a total value of $207,484.12. Following the sale, the insider directly owned 1,012,091 shares of the company’s stock, valued at $2,388,534.76. This represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SPRO. XTX Topco Ltd purchased a new stake in Spero Therapeutics in the second quarter valued at $100,000. Quadrature Capital Ltd purchased a new position in shares of Spero Therapeutics during the 2nd quarter valued at about $90,000. Invesco Ltd. acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at about $43,000. Stonepine Capital Management LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at about $455,000. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Spero Therapeutics in the third quarter worth about $70,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.